Q-omics provides the consensus-scored SDR42E1 profile across patient tissues and cancer cell-line models. SDR42E1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SDR42E1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SDR42E1 RNA expression shows 17,576 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KIRC, and THYM as cancer lineages where SDR42E1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDR42E1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDR42E1 survival associations across molecular data types. SDR42E1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDR42E1 RNA expression–survival associations across cancer types. High SDR42E1 expression shows unfavorable associations in LGG and MESO, but favorable associations in UCS, HNSC, UCEC and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for SDR42E1 RNA expression.
This table summarizes SDR42E1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SDR42E1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDR42E1 shows lower tumor expression in KIRC, THCA, KICH, UCEC and COAD and higher tumor expression in LUSC. The KIRC box plot shows higher SDR42E1 RNA expression in normal versus tumor tissue (log2 FC = −1.231, t-test p < 0.001).
This table shows molecular features associated with SDR42E1 in patient tissues and cancer cell lines. In patient samples, SDR42E1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SDR42E1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
